Immunoassays provide a fast, simple, and cost-effective method of detection with high sensitivity and specificity. They exploit antibodies’ properties to identify pathogens, cancer, and other disease biomarkers, drugs, and other analytes. Without a secure stream of validated monoclonal antibodies (mAbs), IVD developers risk nonspecific binding, batch variability, or loss of supply. At the discovery and development stage, the latter can result in wasted time and resources, or worse, project abandonment, while downstream, during manufacturing, it can lead to substantial costs.
By sequencing the protein of the antibody reagent in parallel to assessing the antibody’s affinity and specificity prior to use, scientists, kit, and reagent manufacturers can eliminate unforeseen surprises. Furthermore, obtaining the protein sequence enables recombinant expression, yielding more consistent batches with predictable biological activity. Next-generation protein sequencing (NGPS) can also help avoid issues with mAbs stemming from cell line drift, gene loss, and gene mutations. Rapid Novor’s NGPS has facilitated the development of reliable kits and immunoreagents securing scientists’ research reproducibility and their trust.